Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (ON 123300) is being evaluated in a Phase II trial. Onconova listed on NASDAQ in 2013.